We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
-23.67%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$36.2M
AUM Growth
-$72M
(-67%)
Cap. Flow
-$56.1M
Cap. Flow
% of AUM
-155.04%
Top 10 Holdings %
Top 10 Hldgs %
74.48%
Holding
38
New
3
Increased
2
Reduced
18
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inogen
INGN
|
+$1.66M |
| 2 |
Equillium
EQ
|
+$846K |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
+$468K |
| 4 |
Insmed
INSM
|
+$208K |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$121K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Healthcare
ACHC
|
+$6.57M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$3.72M |
| 3 |
DaVita
DVA
|
+$3.35M |
| 4 |
AnaptysBio
ANAB
|
+$3.31M |
| 5 |
Pfizer
PFE
|
+$3.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ionis Pharmaceuticals
IONS
$9.4B
| – | – |
-37,021
| Closed | -$1.91M |
|
|
27
Jazz Pharmaceuticals
JAZZ
$16.7B
| – | – |
-22,144
| Closed | -$3.72M |
|
28
Natera
NTRA
$46.4B
| – | – |
-124,517
| Closed | -$2.98M |
|
29
OraSure Technologies
OSUR
$279M
| – | – |
-179,496
| Closed | -$2.77M |
|
|
30
Pfizer
PFE
$153B
| – | – |
-72,000
| Closed | -$3.01M |
|
31
Sarepta Therapeutics
SRPT
$1.77B
| – | – |
-14,508
| Closed | -$2.34M |
|
32
Neuronetics
STIM
$166M
| – | – |
-45,292
| Closed | -$1.45M |
|
33
Vertex Pharmaceuticals
VRTX
$126B
| – | – |
-12,650
| Closed | -$2.44M |
|
|
NVRO
34
DELISTED
NEVRO CORP.
NVRO
| – | – |
-31,379
| Closed | -$1.79M |
|
|
GRTS
35
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| – | – |
-20,000
| Closed | -$285K |
|
|
NVTA
36
DELISTED
Invitae Corporation
NVTA
| – | – |
-105,072
| Closed | -$1.76M |
|
|
UROV
37
DELISTED
Urovant Sciences Ltd.
UROV
| – | – |
-158,463
| Closed | -$1.9M |
|
|
ECYT
38
DELISTED
Endocyte, Inc. Common Stock
ECYT
| – | – |
-96,297
| Closed | -$1.71M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Asymmetry Capital Management held 38 positions worth $36.2M, down 67% from $108M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Asymmetry Capital Management withdrew a net $56.1M in Q4 2018, closing 15 positions and reducing 18 holdings. Its most notable exit was Acadia Healthcare, an estimated $6.57M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier.
Against the trend, Asymmetry Capital Management opened a new position in Inogen worth $1.25M.
- Asymmetry Capital Management's largest Q4 2018 buy was Inogen: 10,072 shares worth $1.25M.
- Asymmetry Capital Management added most to Insmed in Q4 2018, an estimated $208K increase.
- Asymmetry Capital Management's biggest Q4 2018 reduction was DaVita, cutting an estimated $3.35M.
- Asymmetry Capital Management fully exited Acadia Healthcare in Q4 2018, selling an estimated $6.57M.
- Asymmetry Capital Management's ten largest holdings make up 74% of its $36.2M portfolio in Q4 2018.
- Asymmetry Capital Management opened 3 new positions and closed 15 in Q4 2018.
- Asymmetry Capital Management's portfolio value fell 67% quarter-over-quarter to $36.2M.
Based on Asymmetry Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.